Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of $75 million of its shares of common stock. All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15 percent of the number of shares sold in the offering.

BofA Securities and William Blair are acting as joint book-running managers for the proposed offering. Canaccord Genuity is acting as lead manager and BTIG is acting as co-manager.